Teradyne Earnings Surge on AI-Driven Test Demand

Teradyne earnings beat as semiconductor-test sales powered Q2 strength; Q3 guidance topped the Street and lifted extended trading.

July 29, 2026·2 min read
View all news articles
Flat vector of a semiconductor test rack powering up on a light cobalt-silver gradient, showing Teradyne earnings strength.

KEY TAKEAWAYS

  • Reported Q2 revenue of $1.3 billion and non-GAAP EPS of $2.47.
  • Semiconductor Test sales were $1.1 billion and were linked to AI-driven chip testing.
  • Guided Q3 revenue to $1.2-$1.3 billion and shares rose about 13% in extended trading.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Teradyne earnings delivered stronger-than-expected second-quarter results on July 28, 2026, as management said AI-driven chip-testing demand boosted Semiconductor Test sales. The company also issued third-quarter guidance above Wall Street expectations, lifting extended-hours trading.

Q2 2026 Results

Teradyne, Inc. (NASDAQ: TER) reported Q2 2026 revenue of $1.3 billion and non-GAAP earnings per share (EPS) of $2.47 in a press release at 4:35 p.m. ET on July 28. Management attributed the quarter’s strength to AI-related infrastructure investment and semiconductor testing demand.

Semiconductor Test accounted for $1.1 billion of sales, about 84% of total revenue, while Product Test and Robotics contributed $107 million and $100 million, respectively. This concentration highlights Teradyne’s reliance on chip-testing cycles as customers develop more complex AI-oriented devices.

Revenue more than doubled from $652 million a year earlier and edged up from the prior quarter. Non-GAAP EPS rose from $0.57 in Q2 2025 and was slightly below the $2.56 posted in Q1 2026. Net income increased to $375 million from $78 million a year earlier.

Q3 Guidance and Trading Reaction

Teradyne guided third-quarter revenue to a range of $1.2 billion to $1.3 billion and non-GAAP EPS between $1.85 and $2.15, exceeding Wall Street’s average revenue estimate of $1.04 billion. Management framed the outlook around sustained demand for chip testing tied to AI infrastructure, positioning the company to benefit from follow-on spending in wafer fabrication and data-center hardware.

Shares rose about 13% in extended trading after the guidance, with the move visible shortly after market close. Analysts noted management’s bet on a continued rise in wafer-fabrication investment and AI-driven demand for more complex chips, factors that favor suppliers of testing equipment.

The quarter and outlook underscore a shift in Teradyne’s near-term revenue mix, with semiconductor testing carrying the bulk of growth while robotics and product testing remain smaller contributors. This focus explains why the company’s guidance above consensus had an immediate impact on investor sentiment and share price.

Investors will watch how durable the AI-related investment cycle proves and whether wafer-fab spending sustains multi-quarter demand for test systems. The current results and guidance reinforce Teradyne’s strategic emphasis on capturing test and robotics opportunities across wafer production and AI data-center deployments, making semiconductor testing demand central to its near-term outlook.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Plug Power Q2 Results Lift Margins, Raise Outlook

Plug Power Q2 Results Lift Margins, Raise Outlook

Plug Power Q2 results show margin gains and raised revenue guidance, but big losses and planned asset sales leave liquidity execution the key trader risk.

AST SpaceMobile Q2 Results Miss Estimates, Reaffirm Guidance

AST SpaceMobile Q2 Results Miss Estimates, Reaffirm Guidance

AST SpaceMobile Q2 results missed expectations; management reaffirmed 2026 revenue guidance and pointed to a $1.3B backlog as traders weigh cash burn risk.

Cardinal Health Earnings Lift Guidance on Specialty Drugs

Cardinal Health Earnings Lift Guidance on Specialty Drugs

Cardinal Health earnings raised full-year EPS guidance to $12.40 to $12.60 on specialty drug strength, likely prompting repositioning into specialty names.

Super Micro Earnings Preview: Margins and Backlog

Super Micro Earnings Preview: Margins and Backlog

Super Micro earnings preview noted 15%-17% gross margin and a record backlog, putting traders on watch for backlog conversion into revenue and AI demand.

Trump Media Earnings: Q2 Loss Deepens

Trump Media Earnings: Q2 Loss Deepens

Trump Media earnings said non-cash digital-asset writedowns pushed $238.1 million Q2 loss, magnifying asset-price volatility and prompting traders to trim stakes.

Nvidia $500 Billion AI Financing Deal

Nvidia $500 Billion AI Financing Deal

Nvidia $500 billion AI financing pact with six Wall Street firms aims to mobilize capital for compute and data centers and could reprice chip demand.